Merlin logo

Can my patient forgo the sentinel lymph node biopsy?

Sentinel lymph node biopsy referral can be challenging

Especially for the group of melanoma patients for which guidelines recommend to “discuss and consider/offer” the surgery.1

The SLNB is considered the standard of care to determine the clinical stage of the disease and guide appropriate treatment decisions. Still, this is an invasive surgery that may expose a patient to >10% risk of surgery-related complications.2

Furthermore, studies show that the wide majority (80-85%) of melanoma patients who undergo the surgery are negative for nodal metastasis (SLNB -).3 While some patients may require this procedure, many may be able to avoid a SLNB due to the absence of nodal metastases and consequently avoid risks associated with the surgery such as infection, seroma, hematoma and lymphedema.2

The Merlin test addresses this unmet clinical need by triaging cutaneous melanoma patients for sentinel lymph node biopsy based on their risk for nodal metastasis.

Merlin test at a glance

Gene expression-based test to identify primary cutaneous melanoma patients who may forgo SLNB surgery due to their low risk for nodal matastasis.

Enhances clinicopathologic findings with critical tumor biology insights.

Improved performance over clinicopathologic (CP) variables only (e.g. nomograms like MIA and MSKCC6) for appropriately predicting SLN status.7

Validated in multiple multicenter clinical trials in the U.S. and EU.

Non-invasive test that uses primary biopsy tissue.

Delivers test result within 5 business days upon receipt of a compliant sample.

Developed by SkylineDx in collaboration with the Mayo Clinic.

The Merlin test identifies primary cutaneous melanoma patients who may forgo the SLNB due to their low risk for nodal metastasis.

T1-T2 melanomas account for ~86% of the newly diagnosed melanomas. For this group of patients, guidelines recommend to “discuss and consider/offer” SLNB surgery.1

The Merlin test provides unique insights on the aggressiveness of your patient’s melanoma

Current treatment decisions are made based on clinicopathologic factors such as patient’s age, Breslow thickness and ulceration. However, these variables do not always provide a complete view of your patient’s melanoma and the individual corresponding risks.

With the Merlin test, you can gain a deeper understanding of your patient’s cancer with no additional procedure required.

The Merlin test uses the CP-GEP model, an algorithm developed by logistic regression modeling. The combination of clinicopathologic factors – patient’s age and Breslow thickness – with the gene expression profiling component of 8 specific genes involved in cancer metastasis and melanosome biogenesis, will allow you to better understand your patient’s risk and may optimize a personalized treatment plan.

The Merlin test supports your decision-making

The Merlin test may help you optimize the clinical management of each patient. Validation studies in the United States and Europe confirm that the test accurately identifies patients who have a low risk for nodal metastasis. The test provides a binary result:

OR

The Merlin test makes use of the biopsy tissue collected for diagnosis.

Low Risk Report

Low Risk Report

High Risk Report

High Risk Report

The Merlin test may reduce the number of SLNB-related complications by 59% when Low Risk patients forgo SLNB surgery.5

Merlin EU Kit

Tissue requirements

  • 5 x 10μm formalin fixed and paraffin embedded (FFPE) tissue of primary cutaneous melanoma biopsy mounted on glass slides (charged, unstained, unbaked) and placed in slide box mailer included in kit.
  • No macrodissection is needed.

Merlin test indication

Utility

Identify primary cutaneous melanoma patients who have a low risk of having nodal metastasis and may therefore forgo the sentinel lymph node biopsy.

Intended use population

SLNB eligible patients:

Newly diagnosed invasive malignant melanoma of the skin (AJCC 8th edition staging guidelines)

Without clinical evidence of nodal involvement or distant metastasis (cN0M0)

pT1b-pT3 melanomas (Breslow thickness ≥ 0.8mm to 4mm or <0.8mm with ulceration)

pT1a (Breslow thickness < 0.8 mm) and one or more of the following:

  • Mitotic rate ≥ 2/mm2
  • Patient age at time of primary biopsy < 40 years old
  • Presence of lymphovascular invasion
  1. Swetter S.M., Tsao H., Bichakjian C.K., et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–250.
  2. Moody JA, Ali RF, Carbone AC, et al: Complications of sentinel lymph node biopsy for melanoma – A systematic review of the literature. Eur J Surg Oncol 43:270-277, 2017
  3. Morton DL, Thompson JF, Cochran AJ, et al: Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599-609, 2014
  4. Shaikh WR, Dusza SW, Weinstock MA, et al: Melanoma Thickness and Survival Trends in the United States, 1989-2009. J Natl Cancer Inst. 2016
  5. Hieken, T.J., Sadurní, M.B., Quattrocchi, et al: Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study. Int J Dermatol. 2022
  6. Johansson I, Tempel D, Dwarkasing D, et al. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. EJSO. 2021: DOI 10.1016/j. ejso.2021.11.010.
  7. Bellomo D, Arias-Mejias S, Ramana C, et al. A model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precis Oncol. 2020:DOI 10.1200/PO.19.00206.